Literature DB >> 3123277

Concomitant gonadotropin-releasing hormone agonist and menotropin treatment for the synchronized induction of multiple follicles.

R Palermo1, G Amodeo, D Navot, Z Rosenwaks, E Cittadini.   

Abstract

In an effort to overcome possible interference by endogenous gonadotropin-ovarian hormone dynamics, desensitization of the pituitary gonadotropins by a gonadotropin-releasing hormone agonist (GnRHa) was achieved in 12 women with repeatedly failed attempts at multiple follicular stimulation. Eight women were scheduled for in vitro fertilization (IVF) and embryo transfer (ET), and 4 for gamete intrafallopian transfer (GIFT). Stimulation failure was characterized by premature luteinization, poor estradiol (E2) response, or inadequate follicular growth. The agonist was administered by nasal spray 500 to 600 micrograms/day beginning on days 21 to 23 of the menstrual cycle. A rapid desensitization occurred by 7.6 +/- 0.6 days (mean +/- standard error [SE]) following the initial dose. Gonadotropin stimulation was begun when pituitary and ovarian suppression was judged to be adequate. In response to gonadotropin stimulation, a continuous rise of E2 was observed in all patients with a mean of 989 +/- 46 pg/ml on the day of hCG. A cohort of synchronized follicles was recruited and matured. The mean number of growing follicles per patient was significantly higher (P less than 0.0001) in combined therapy than in previously failed cycles (8.0 +/- 0.3 versus 3.2 +/- 0.1). All the patients underwent oocyte retrieval and 94.3% of the harvested oocytes were preovulatory. A high fertilization rate (89.7%) of the inseminated oocytes occurred in IVF patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3123277     DOI: 10.1016/s0015-0282(16)59718-0

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  11 in total

1.  Improved pregnancy outcome with gonadotropin releasing hormone agonist (GnRH-a) stimulation is due to the improvement in oocyte quantity rather than quality.

Authors:  H C Liu; Y M Lai; O Davis; A S Berkeley; M Graf; J Grifo; J Cohen; Z Rosenwaks
Journal:  J Assist Reprod Genet       Date:  1992-08       Impact factor: 3.412

Review 2.  Clinical applications of GnRH analogs.

Authors:  G Forti
Journal:  J Endocrinol Invest       Date:  1988-11       Impact factor: 4.256

3.  Ovarian hyperstimulation associated with the sole use of leuprolide for ovarian suppression.

Authors:  J Yeh; R L Barbieri; V A Ravnikar
Journal:  J In Vitro Fert Embryo Transf       Date:  1989-08

4.  Effects of a gonadotropin releasing hormone agonist on oocyte maturation, fertilization, and embryonal development of mice.

Authors:  B C Yang; T Uemura; H Minaguchi
Journal:  J Assist Reprod Genet       Date:  1995-11       Impact factor: 3.412

5.  Follicular fluid steroid content and in vitro steroid secretion by granulosa-lutein cells from individual follicles among different stimulation protocols for in vitro fertilization-embryo transfer.

Authors:  G A Hill; K G Osteen
Journal:  J In Vitro Fert Embryo Transf       Date:  1989-08

6.  The use of gonadotropin releasing hormone agonist (GnRHa) in good responders undergoing repeat in vitro fertilization/embryo transfer (IVF/ET).

Authors:  J H Segars; G A Hill; S H Bryan; C M Herbert; K G Osteen; B J Rogers; A C Wentz
Journal:  J In Vitro Fert Embryo Transf       Date:  1990-12

7.  GnRH antagonist improved blastocyst quality and pregnancy outcome after multiple failures of IVF/ICSI-ET with a GnRH agonist protocol.

Authors:  Katsuhiko Takahashi; Tetsunori Mukaida; Tatsuhiro Tomiyama; Tetsuya Goto; Chikahiro Oka
Journal:  J Assist Reprod Genet       Date:  2004-09       Impact factor: 3.412

8.  Impact of leuprolide acetate on the response to follicular stimulation for in vitro fertilization in patients with normal basal gonadotropin levels.

Authors:  R G Brzyski; G S Jones; S Oehninger; A A Acosta; C H Kruithoff; S J Muasher
Journal:  J In Vitro Fert Embryo Transf       Date:  1989-10

9.  The predictive value of serum progesterone and 17-OH progesterone levels on in vitro fertilization outcome.

Authors:  M J Levy; D B Smotrich; E A Widra; A W Sagoskin; D L Murray; J L Hall
Journal:  J Assist Reprod Genet       Date:  1995-03       Impact factor: 3.412

10.  The effects of gonadotropin-releasing hormone agonist on androstenedione production and follicular development during controlled ovarian hyperstimulation.

Authors:  K Akaboshi; T Oda; J Yoshida; S Kohriyama; T Miyazaki; Y Yoshimura
Journal:  J Assist Reprod Genet       Date:  1998-09       Impact factor: 3.412

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.